BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 23924796)

  • 1. Target-mediated drug disposition and prolonged liver accumulation of a novel humanized anti-CD81 monoclonal antibody in cynomolgus monkeys.
    Vexler V; Yu L; Pamulapati C; Garrido R; Grimm HP; Sriraman P; Bohini S; Schraeml M; Singh U; Brandt M; Ries S; Ma H; Klumpp K; Ji C
    MAbs; 2013; 5(5):776-86. PubMed ID: 23924796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Agonistic TAM-163 antibody targeting tyrosine kinase receptor-B: applying mechanistic modeling to enable preclinical to clinical translation and guide clinical trial design.
    Vugmeyster Y; Rohde C; Perreault M; Gimeno RE; Singh P
    MAbs; 2013; 5(3):373-83. PubMed ID: 23529133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of a Target-Mediated Drug Disposition Model to Predict the Human Pharmacokinetics and Target Occupancy of GC1118, an Anti-epidermal Growth Factor Receptor Antibody.
    Park WS; Han S; Lee J; Hong T; Won J; Lim Y; Lee K; Byun HY; Yim DS
    Basic Clin Pharmacol Toxicol; 2017 Mar; 120(3):243-249. PubMed ID: 27637171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of an anti-TFPI monoclonal antibody (concizumab) blocking the TFPI interaction with the active site of FXa in Cynomolgus monkeys after iv and sc administration.
    Agersø H; Overgaard RV; Petersen MB; Hansen L; Hermit MB; Sørensen MH; Petersen LC; Hilden I
    Eur J Pharm Sci; 2014 Jun; 56():65-9. PubMed ID: 24568891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Target-mediated drug disposition model: relationships with indirect response models and application to population PK-PD analysis.
    Gibiansky L; Gibiansky E
    J Pharmacokinet Pharmacodyn; 2009 Aug; 36(4):341-51. PubMed ID: 19578985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Target-mediated drug disposition modeling of an anti-TFPI antibody (MG1113) in cynomolgus monkeys to predict human pharmacokinetics and pharmacodynamics.
    Kwak EY; Kim MJ; Park JH; Jung HW; Jung ME
    J Thromb Haemost; 2021 Jun; 19(6):1425-1435. PubMed ID: 33448093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Target-mediated drug disposition model for drugs that bind to more than one target.
    Gibiansky L; Gibiansky E
    J Pharmacokinet Pharmacodyn; 2010 Aug; 37(4):323-46. PubMed ID: 20669044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective analysis of model-based predictivity of human pharmacokinetics for anti-IL-36R monoclonal antibody MAB92 using a rat anti-mouse IL-36R monoclonal antibody and RNA expression data (FANTOM5).
    Ahlberg J; Giragossian C; Li H; Myzithras M; Raymond E; Caviness G; Grimaldi C; Brown SE; Perez R; Yang D; Kroe-Barrett R; Joseph D; Pamulapati C; Coble K; Ruus P; Woska JR; Ganesan R; Hansel S; Mbow ML
    MAbs; 2019 Jul; 11(5):956-964. PubMed ID: 31068073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A target-mediated drug disposition population pharmacokinetic model of GC1118, a novel anti-EGFR antibody, in patients with solid tumors.
    Chung TK; Lee HA; Park SI; Oh DY; Lee KW; Kim JW; Kim JH; Woo A; Lee SJ; Bang YJ; Lee H
    Clin Transl Sci; 2021 May; 14(3):990-1001. PubMed ID: 33382918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complex PK-PD of an engineered IL-15/IL-15Rα-Fc fusion protein in cynomolgus monkeys: QSP modeling of lymphocyte dynamics.
    Lu D; Yadav R; Holder P; Chiang E; Sanjabi S; Poon V; Bernett M; Varma R; Liu K; Leung I; Bogaert L; Desjarlais J; Shivva V; Hosseini I; Ramanujan S
    Eur J Pharm Sci; 2023 Jul; 186():106450. PubMed ID: 37084985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Framework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge.
    Li B; Tesar D; Boswell CA; Cahaya HS; Wong A; Zhang J; Meng YG; Eigenbrot C; Pantua H; Diao J; Kapadia SB; Deng R; Kelley RF
    MAbs; 2014; 6(5):1255-64. PubMed ID: 25517310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models.
    Yan X; Mager DE; Krzyzanski W
    J Pharmacokinet Pharmacodyn; 2010 Feb; 37(1):25-47. PubMed ID: 20012173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, Pharmacodynamics, and Safety of E6011, a Novel Humanized Antifractalkine (CX3CL1) Monoclonal Antibody: A Randomized, Double-Blind, Placebo-Controlled Single-Ascending-Dose Study.
    Tabuchi H; Katsurabara T; Mori M; Aoyama M; Obara T; Yasuda N; Kawano T; Imai T; Ieiri I; Kumagai Y
    J Clin Pharmacol; 2019 May; 59(5):688-701. PubMed ID: 30575978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies.
    Cao Y; Jusko WJ
    J Pharmacokinet Pharmacodyn; 2014 Aug; 41(4):375-87. PubMed ID: 25077917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mice Expressing Minimally Humanized CD81 and Occludin Genes Support Hepatitis C Virus Uptake In Vivo.
    Ding Q; von Schaewen M; Hrebikova G; Heller B; Sandmann L; Plaas M; Ploss A
    J Virol; 2017 Feb; 91(4):. PubMed ID: 27928007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical Development of an anti-5T4 Antibody-Drug Conjugate: Pharmacokinetics in Mice, Rats, and NHP and Tumor/Tissue Distribution in Mice.
    Leal M; Wentland J; Han X; Zhang Y; Rago B; Duriga N; Spriggs F; Kadar E; Song W; McNally J; Shakey Q; Lorello L; Lucas J; Sapra P
    Bioconjug Chem; 2015 Nov; 26(11):2223-32. PubMed ID: 26180901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EWI-2 is a new component of the tetraspanin web in hepatocytes and lymphoid cells.
    Charrin S; Le Naour F; Labas V; Billard M; Le Caer JP; Emile JF; Petit MA; Boucheix C; Rubinstein E
    Biochem J; 2003 Jul; 373(Pt 2):409-21. PubMed ID: 12708969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetic and pharmacodynamic modeling of MNRP1685A in cynomolgus monkeys using two-target quasi-steady-state (QSS) model.
    Xin Y; Xiang H; Jin D; Theil FP; Joshi A; Damico-Beyer LA; Bai S
    J Pharmacokinet Pharmacodyn; 2012 Apr; 39(2):217-26. PubMed ID: 22382554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel monoclonal anti-CD81 antibody produced by genetic immunization efficiently inhibits Hepatitis C virus cell-cell transmission.
    Fofana I; Xiao F; Thumann C; Turek M; Zona L; Tawar RG; Grunert F; Thompson J; Zeisel MB; Baumert TF
    PLoS One; 2013; 8(5):e64221. PubMed ID: 23704981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Target-mediated drug disposition model for drugs with two binding sites that bind to a target with one binding site.
    Gibiansky L; Gibiansky E
    J Pharmacokinet Pharmacodyn; 2017 Oct; 44(5):463-475. PubMed ID: 28725976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.